What Vitrafy Life Sciences does

Vitrafy Life Sciences is an Australian biotechnology company that develops cold-chain cryopreservation solutions for biomedical and life-science applications. Its core offering is an integrated ecosystem combining the Guardion hardware device, which performs controlled-rate freezing without liquid nitrogen using a proprietary cascade refrigeration system, and the LifeChain software platform, which generates material-specific freeze curves, orchestrates workflows, and provides end-to-end traceability. The system is targeted at three primary verticals: blood and blood products (including platelets and red blood cells), cell and gene therapy manufacturing, and animal reproduction (including aquaculture and livestock).

The company's technology differentiation rests on ultra-fast freezing (under five minutes versus traditional hour-long protocols), elimination of liquid nitrogen handling, and precision thermal control demonstrated across published outcomes — 94% post-thaw T-cell viability (versus 95% fresh), greater than 89% platelet recovery in no-wash conditions, and 72% post-thaw quality for salmon milt versus less than 40% with previous methods. Guardion is manufactured under ISO13485, LifeChain is 21 CFR Part 11 compliant, and FDA registration is in progress for multiple cell types.

Vitrafy generates revenue through hardware sales of Guardion units, subscription or licensing of the LifeChain software, and partnership/licensing arrangements with channel and co-development partners. Enterprise sales are conducted via direct field sales supported by a Southern California demonstration facility, with a 12-month strategic commercial agreement with IMV Technologies providing global reach into the animal reproduction market. The company is publicly listed on the ASX (ASX:VFY), headquartered in Melbourne, Australia, and employs between 11 and 50 people. Named enterprise counterparties include Vitalant, IMV Technologies, BioBridge Global, the U.S. Army Institute of Surgical Research, and Huon Aquaculture.

Name

Vitrafy Life Sciences

Legal name

Vitrafy Life Sciences Limited

Website

https://vitrafy.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Vitrafy Life Sciences is an Australian-listed biotechnology company that builds liquid-nitrogen-free cryopreservation hardware (Guardion) and workflow software (LifeChain) for blood services, cell and gene therapy manufacturers, and animal reproduction companies.

Ownership category

akta.pro rank

Product category

Cryopreservation Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

akta.pro secondary industries

Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC) (HLAMANAJ)

Keywords

• Cryopreservation technology
• Controlled rate freezing
• Biomedical cold chain
• Cell therapy preservation
• Cryogenic storage systems

Headquarters

HQ city

Ballarat

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Guardion Cryopreservation Device Sales: Sale of Guardian cryopreservation hardware units. Class 2 medical device (510(k) exempt and research use). Manufactured under ISO13485. FDA registration upcoming in 1H 2026 for sperm, OVA, blood platelets, red blood cells.
2. LifeChain Software Platform: Enterprise workflow management software providing intelligent cryopreservation orchestration. Sold as subscription or license to labs and manufacturing facilities requiring traceability and compliance.
3. Partnership Revenue - IMV Technologies: Revenue from strategic commercial agreement with IMV Technologies for farm animal and aquaculture cryopreservation. Creates immediate revenue opportunities through global market access via IMV's platform processing over 500 million animal inseminations annually.
4. Partnership Revenue - Vitalant: Revenue from deployment of Guardian cryopreservation freezing units to Vitalant's Colorado premises for red blood cell preservation ecosystem development.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Vitrafy develops and sells an integrated cryopreservation ecosystem combining the Guardion hardware device (an LN2-free, controlled-rate freezer using cascade refrigeration) with the LifeChain software platform (an AI-driven workflow orchestration and traceability system). The solution enables ultra-fast freezing of biological materials—including blood platelets, red blood cells, T-cells, and animal reproductive materials—in under five minutes without liquid nitrogen, targeting blood services, cell and gene therapy manufacturers, and animal reproduction companies.

Product overview

Vitrafy offers a unified cryopreservation ecosystem comprising two integrated products: Guardion™ (hardware) and LifeChain™ (software). Guardion is an LN₂-free cryopreservation device that delivers ultra-fast, precision-controlled freezing in under 5 minutes using cascade refrigeration, designed for scalability from research use to GMP manufacturing. LifeChain is the intelligent orchestration platform that connects users and devices, providing data-driven freeze curve optimization, full traceability, IoT device integration, and multi-site standardization. Together, these products form an end-to-end cryopreservation solution spanning sample collection through application, targeting blood and blood products, cell and gene therapy, and animal reproduction verticals.

Differentiator

Problem solved

Functional benefit

Brands

• Guardion™: LN₂-free cryopreservation system engineered for precision, speed and ease of use. Features ultra-fast freezing without liquid nitrogen, cascade refrigeration system, 30L tank capacity, and integrated touchscreen with LifeChain-generated freeze curves.
• LifeChain™

Products and services

• Guardion™ The Guardion device is an LN2-free, controlled-rate cryopreservation system that uses cascade refrigeration to deliver ultra-fast freezing in under five minutes. It supports blood platelets, red blood cells, T-cells, and animal reproductive materials, with precision thermal control that minimizes cryoinjury. It is a Class 2 medical device manufactured under ISO 13485, sold to blood centers, cell therapy manufacturers, and research institutions.
• LifeChain™ LifeChain is a software platform that orchestrates cryopreservation workflows, generates material-specific freeze curves using proprietary algorithms, and provides full sample traceability and chain-of-custody. It integrates with Guardion hardware and enables multi-site standardization with auditable data entry. It is sold to labs and manufacturing facilities requiring traceability and 21 CFR Part 11 compliance.

Quantifiable outcome

• 94% T-cell post-thaw viability (vs 95% fresh) at 24 hours, maintained at 93% through 72 hours
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Vitalant Innovation CentrecoreStrategic or Co-development Partner · 2 June 2026Partnership to configure Vitrafy's next-generation cryopreservation ecosystem for red blood cells, addressing urgent market need created by impending discontinuation of legacy glycerol-based freezing technologies expected in 2027. Partnership aims to preserve US blood network's ability to maintain cryopreserved RBC stockpiles for emergency response, particularly for rare blood types and mass-casualty events. Vitrafy will initially deploy two cryopreservation freezing units to Vitalant's Colorado premises, with placement expected to support broader market and government engagement toward unified response.
• IMV TechnologiescoreChannel Partner/ Reseller/ Distributor · 22 January 202612-month Strategic Commercial Agreement to jointly commercialize global cryopreservation offering for farm animals and aquaculture. Partnership integrates Vitrafy's nitrogen-free cryopreservation technology with IMV's existing global animal reproduction platform, which processes over 500 million animal inseminations annually. Creates immediate revenue opportunities and positions company for long-term growth through global market access.
• U.S. Army Institute of Surgical ResearchcoreStrategic or Co-development Partner · 22 July 2025Partnership for evaluation of innovative method for preserving blood cells that control clotting (platelets). Phase 1 study showed ~89% platelet recovery rates. Results suggest cryopreserved platelets have potential to be game changer for Warfighters, especially in large-scale combat operations and resource-constrained environments. Phase II testing completed with promising results expected in Q4.
• BioBridge GlobalminorStrategic or Co-development PartnerPhase 1 non-clinical study collaboration showing post-thaw T-cell viability comparable to fresh—an important step toward standardized, higher-quality cryopreservation for cell and gene therapy applications like CAR-T treatments.
• Huon AquacultureminorStrategic or Co-development PartnerPartnership to solve cryopreservation for fish sperm. Vitrafy's cryopreservation solution delivered highest post-thaw quality and best fertilization outcomes in company's breeding program history. Quote from David Mitchell, General Manager Technical: 'Vitrafy's cryopreservation technology has transformed the performance of our breeding program. This is a solution I can see being adopted globally, because it will move our entire industry forward.'

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cytiva: Global bioprocessing and life sciences tools provider (formerly GE Healthcare Life Sciences) offering controlled-rate freezers, cryopreservation media, and bioprocessing equipment. Competes with Vitrafy across blood, CGT, and bioprocessing customer segments but as part of a much broader portfolio.
• Thermo Fisher Scientific: Massive life sciences tools company with cryopreservation products (e.g., Mr. Frosty controlled-rate freezers, Nalgene cryo supplies, CTS cryopreservation media) used across blood banking, CGT, and reproductive medicine. A dominant incumbent with deep distribution that Vitrafy must displace.
• Brooks Life Sciences: Provider of automated cold-chain storage and sample management for biobanks, pharma, and research institutions. Overlaps with Vitrafy's LifeChain software and cryogenic storage use cases, but with a focus on storage rather than active cryopreservation processes.
• Sartorius: Global bioprocessing supplier offering cell and gene therapy manufacturing solutions including cryopreservation equipment, bioprocess automation, and quality control tools. A broader-portfolio competitor serving overlapping CGT and bioprocess customers.

Direct peers

• BioLife Solutions: Specialized supplier of cryopreservation media (CryoStor, HypoThermosol) and biopreservation tools for cell and gene therapy and regenerative medicine. Closest direct competitor to Vitrafy in the CGT cryopreservation workflow, focused on consumables and storage rather than hardware freezing devices.
• Planer: UK-based specialist in controlled-rate freezers for cell therapy, IVF, blood banking, and regenerative medicine. The most direct hardware competitor to Vitrafy's Guardion in the controlled-rate freezing niche with comparable enterprise and clinical customer base.
• Cryoport Systems: Specialized cold-chain logistics provider for life sciences, including cryogenic shipping, biostorage, and temperature-controlled supply chain for cell therapies and reproductive medicine. Complementary to Vitrafy's hardware focus with adjacent cryogenic logistics and chain-of-custody capabilities.

Emerging players

• STEMCELL Technologies: Specialized life sciences tools provider for cell biology, regenerative medicine, and cell therapy workflows including cryopreservation media and protocols. Comparable target customer base (CGT manufacturers and academic researchers) but focused on reagents rather than freezing hardware.
• Chart Industries: Industrial cryogenic equipment supplier with growing life sciences presence (formerly MVE Biological Solutions) including LN₂ storage and cryogenic freezers. Comparable cryogenic technology stack with focus on storage rather than active cryopreservation processes targeting Vitrafy's customer verticals.

Regional players

• Haier Biomedical: Large Chinese manufacturer of ultra-low temperature freezers, cryogenic storage, and laboratory cold-chain equipment. Operates in adjacent cold-chain and cryo storage categories with strong APAC distribution — comparable product category but more emphasis on storage than process freezing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vitrafy
• Facebookweb.facebook.com/vitrafylifesciences
• LinkedInlinkedin.com/company/vitrafy-life-sciences
• Instagraminstagram.com/vitrafy

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitrafy Life Sciences